Alaric lives in New York and has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.
Latest From Alaric DeArment
The FDA granted accelerated approval for the small but significant HER2-mutated NSCLC indication, while the arbitrator in Seagen’s arbitration case ruled in Daiichi Sankyo’s favor.
Without disclosing data, 2seventy and BMS reported positive Phase III results in third-line and beyond multiple myeloma, but Carvykti will soon have second-line data.
The company presented data for its bispecific antibody tarlatamab at WCLC, drawing noticeably more excitement than highly anticipated but disappointing data for Lumakras with checkpoint inhibitors.
Data presented during the weekend at WCLC for Lumakras with Keytruda or Tecentriq raised questions about elevated liver toxicity and a lackluster response rate.
An analyst had suggested that in the event of a thumbs-down from the FDA, the company could end up focusing on other catalysts instead.
Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.